Introduction: Active surveillance needs a precise grading diagnosis of a low-grade carcinoma of the prostate (Gleason score (GS) 6) within a small organ-confined tumor. However, how accurate is the gold standard of GS 6 in predicting a small pT2 carcinoma? To answer this question, we have analyzed grading systems in this study. Methods: Prostatic carcinomas in biopsy and corresponding radical prostatectomy (RP) specimens of 960 patients were graded by the Gleason system in which glandular fusions and nucleolar stage (prominence and location) were considered. Results: Using the modified Gleason grading, a high upgrading rate from the biopsy to RP specimens (GS 6–7) and in even 30% a non-organ-confined growth pattern (pT3) of GS 6 carcinoma in RP was found. When considering glandular fusion and the incorporation of the state of nucleoli within the Gleason grading, the agreement of score 6 between biopsy and RP specimens as well as the prediction of a pT2a tumor increased from about 80 to 90%. Conclusion: The combination of Gleason grading and grading of the nuclear and nucleolar features may help to identify patients eligible for active surveillance.

Keywords:
Low-grade carcinoma of the prostate, Stage pT2a, Gleason 6, Active surveillance
1.
Epstein JI, Algaba F, Allsbrook WC, et al: Acinar adenocarcinoma in tumours of the prostate; in Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds): WHO Classification of Tumours of Urinary System and Male Genital Organs. Lyon, IARC, 2004, pp 180–181.
2.
Colleselli D, Pelzer AE, Steiner E, et al: Upgrading of Gleason score 6 prostate cancers on biopsy after prostatectomy in the low and intermediate tPSA range. Prostate Cancer Prostatic Dis 2010;13:182–185.
3.
Kvale R, Moller B, Wahlqvist R, et al: Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study. BJU Int 2009;103:1647–1654.
4.
Egevad L: Recent trends in Gleason grading of prostate cancer. II. Prognosis, reproducibility and reporting. Anal Quant Cytol Histol 2008;30:254–260.
5.
Helpap B, Egevad L: The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Arch 2006;449:622–627.
6.
Delahunt B, Miller RJ, Srigley JR, et al: Gleason grading: past, present and future. Histopathology 2012;60:75–86.
7.
Helpap B, Egevad L: Modified Gleason grading. An updated review. Histol Histopathol 2009;24:661–666.
8.
Partin AW, Kattan MW, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 1997;277:1445–1451.
9.
Raagde H, Korb LJ, Elgamad AA, et al: Modern prostate brachytherapy: prostate-specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 2000;89:135–141.
10.
Choo R, Klotz L, Danjoux C, et al: Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate-specific antigen, histological and/or clinical progression. J Urol 2002;167:1664–1669.
11.
Dall’Era MA, Cooperberg MR, Chan JM: Active surveillance for early stage prostate cancer. Cancer 2008;112:1650–1659.
12.
Klotz L, Zhang L, Lam A, et al: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2009;28:126–131.
13.
Tosoian JJ, Trock BJ, Landis P, et al: Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185–2190.
14.
Kawachi MH, Bahnson RR, Barry M, et al: Prostate cancer early detection. J Natl Compr Canc Netw 2010;8:240–262.
15.
DGU: Interdisciplinary guideline of quality S3 for early detection, diagnosis and therapy of prostate carcinoma of different clinical stages. DGU, 2011, version 1.03.
16.
Heidenreich A, Bellmunt J, Bolla M, et al: EAU guidelines on prostate cancer. Eur Urol 2011;59:61–71.
17.
Helpap B, Kristiansen G, Beer M, et al: The significance of fused glands of Gleason 3 + 4 = 7a of prostate cancer. Pathologe 2011;32:106.
18.
Helpap B, Kristiansen G, Beer M, et al: Improving the reproducibility of the Gleason scores in small foci of prostate cancer – suggestion of diagnostic criteria for glandular fusion. Pathol Oncol Res 2012;18:615–621.
19.
Helpap B, Köllermann J: Combined histoarchitectural and cytological biopsy grading improves grading accuracy in low grade prostate cancer. Int J Urol 2012;19:126–133.
20.
Helpap B, Kristiansen G, Köllermann J, et al: Significance of Gleason grading in a clinical setting that considers active surveillance as a therapeutic option of prostatic low grade cancer. Pathologe 2012;33(suppl 1):164.
21.
Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, ISUP Grading Committee: The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228–1242.
22.
Epstein JI: Diagnosis of limited adenocarcinoma of the prostate. Histopathology 2012;60:28–40.
23.
Latour M, Amin MB, Billis A, et al: Grading of invasive cribriform carcinoma on prostate needle biopsy. An interobserver study among experts in genitourinary pathology. Am J Surg Pathol 2008;32:1532–1539.
24.
Lotal TL, Epstein JI: Clinical implications of changing definitions within the Gleason grading system. Nat Rev Urol 2010;7:136–142.
25.
Mostofi FK, Sesterhenn IA, Davis CJ: Histological typing of prostate tumours; in World Health Organization International Histological Classification of Tumours. Berlin, Springer, 2002.
26.
Helpap B: Review of the morphology of prostatic carcinoma with special emphasis on subgrading and prognosis. J Urol Pathol 1993;1:3–19.
27.
Epstein JI: An update of Gleason grading system. J Urol 2010;183:433–440.
28.
Allsbrook WC Jr, Mangold KA, Johnson MH, et al: Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol 2001;32:81–88.
29.
Allsbrook WC Jr, Mangold KA, Johnson MH, et al: Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol 2001;32:74–80.
30.
Melia J, Moseley R, Griffiths DFR, et al: A UK-based investigation of inter- and intra-observer reproducibility of Gleason grading of prostatic biopsies. Histopathology 2006;48:644–654.
31.
Egevad L, Algaba F, Berney DM, et al: Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading. Virchows Arch 2011;459:175–182.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.